|
Association of ECOG performance status with efficacy in patients receiving panitumumab with best supportive care (BSC) vs BSC alone for chemorefractory metastatic colorectal cancer. |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Biogen; Merck; Novartis; Pfizer; Roche |
Speakers' Bureau - Amgen; AstraZeneca; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
|
Consulting or Advisory Role - Amgen; Roche |
Travel, Accommodations, Expenses - Amgen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Sandoz; Teva |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Teva |
Travel, Accommodations, Expenses - Astellas Pharma; Teva |
|
|
Honoraria - II Dong Pharmaceuticals; Roche |
Consulting or Advisory Role - Bayer |
|
|
No Relationships to Disclose |
|
|
Expert Testimony - AstraZeneca; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Amgen; Amgen (I) |
Stock and Other Ownership Interests - Amgen; Amgen (I) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Research Funding - Bayer (Inst); Merck Serono (Inst); Roche (Inst) |